Background: The findings will help guide the development of targeted antimicrobial stewardship programs and enhance public health strategies to address resistance. Aim: This study aimed to identify common antimicrobial-resistant organisms and their resistance profiles in clinical specimens from a tertiary care hospital. Settings and Design: A cross-sectional study was conducted at ACS Medical College and Hospital, Chennai, from November 2023 to May 2024, involving 346 participants. Materials and Methods: Clinical specimens, including urine, blood, sputum, and wound swabs, were collected from patients in various hospital wards. Demographic details of participants were documented, and patients who had received antimicrobial therapy within the previous month or provided tissue samples were excluded. The specimens were analyzed in the central laboratory for microbial growth and antimicrobial resistance profiles. Isolated were tested by Kirby-Bauer disc diffusion method and breakpoint minimum inhibitory concentration for susceptibility against standard antibiotics. Results: Among the 346 specimens analyzed, 264 (76.3%) showed microbial growth. The most commonly isolated organisms were Escherichia coli (28.8%), Klebsiella species (26.9%). High level resistance was observed, especially to Polymyxin B (98.7%), Cefoperazone/Sulbactam (97.4%), and Cefotaxime (92.1%). Conclusion: antimicrobial resistance requires coordinated action across healthcare, policy, and public sectors. By enforcing stricter regulations, enhancing surveillance, and investing in new treatments, we can slow resistance and preserve the effectiveness of antibiotics, safeguarding public health for future generations.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Dr. M.G.R Educational and Research institute gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript